Author | Casagrande, Thays Zanon | |
Author | Rocha, Ismael Artur da Costa | |
Author | Gavi, Maria Bernadete Renoldi de Oliveira | |
Author | Miyamoto, Samira Tatiyama | |
Author | Martins, Priscila Costa | |
Author | Serrano, Érica Vieira | |
Author | Dinis, Valquiria Garcia | |
Author | Machado, Ketty Lysie Libardi Lira | |
Author | Gouvea, Sonia Alves | |
Author | Caser, Larissa Carvalho | |
Author | Azevedo, Ana Carolina Campi | |
Author | Carvalho, Andréa Teixeira de | |
Author | Pascoal, Vanessa Peruhype Magalhães | |
Author | Bissoli, Maria de Fatima | |
Author | Gouvea, Maria da Penha Gomes | |
Author | Lima, Sheila Maria Barbosa de | |
Author | Miranda, Emily Hime | |
Author | Trindade, Gisela Freitas | |
Author | Lyra, Danielle Grillo Pacheco | |
Author | Burian, Ana Paula Neves | |
Author | Pinto Neto, Lauro Ferreira da Silva | |
Author | Mota, Licia Maria Henrique da | |
Author | Martins Filho, Olindo Assis | |
Author | Valim, Valéria | |
Access date | 2023-01-25T18:51:50Z | |
Available date | 2023-01-25T18:51:50Z | |
Document date | 2022 | |
Citation | CASAGRANDE, Thays Zanon et al. Previous biological therapy and impairment of the IFN-γ/IL-10 axis are associated with low immune response to 17DD-YF vaccination in patients with spondyloarthritis. Vaccine, v. 40, n. 32, p. 4580-4593, 2022. doi: 10.1016/j.vaccine.2022.05.071. | en_US |
ISSN | 0264-410X | en_US |
URI | https://www.arca.fiocruz.br/handle/icict/56617 | |
Language | eng | en_US |
Publisher | Elsevier Science | en_US |
Rights | restricted access | en_US |
Title | Previous biological therapy and impairment of the IFN-γ/IL-10 axis are associated with low immune response to 17DD-YF vaccination in patients with spondyloarthritis | en_US |
Type | Article | en_US |
Abstract | Yellow fever (YF) vaccination is known to induce a suboptimal response in patients with autoimmune diseases (AIDs). To date, few studies have focused on the performance of 17DD-YF vaccination in patients with spondyloarthritis (SpA). In general, patients with SpA are young and have less comorbidities than other patients with AIDs, and frequently receive biological disease-modifying antirheumatic drugs (DMARDs) that may impact their response to vaccines. Taking this background information, the present study aimed to investigate whether the use of biological DMARDs, even after planned washout, or disease activity measured by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), would impact the overall performance of planned 17DD-YF primary vaccination in patients with SpA. For this purpose, 74 subjects were enrolled in a prospective study, including adult patients with SpA (SpA; n = 51) and a healthy control (HC; n = 23) group. Analysis of YF specific neutralizing antibodies test (PRNT), along with YF viremia and the levels of serum chemokines, cytokines, and growth factors were performed at distinct time points (D0, D3, D4, D5, D6, D7, D14, and D28). The BASDAI scores were evaluated at D0 and D180. Data demonstrated that overall, the SpA group presented lower PRNT titers and seropositivity rates as compared to the HC group (GeoMean = 112 vs. 440; 73% vs. 96%, respectively). In SpA subgroup analyses, previous biological DMARDs (BIO-IT) led to a lower PRNT titers (BIO-IT 79, 95% CI [39-150] vs. without biological DMARDs [non-BIO-IT] 159, 95% CI [94-267], p < 0.001). The non-BIO-IT group achieved a response similar to the HC group (81% vs. 96%, p = 0.112), whereas the BIO-IT group had a lower seroconversion rate (64% vs. 96% HC, p = 0.007). The BASDAI was not associated with PRNT levels and did not change after 6 months of follow-up. No differences in YF viremia were observed amongst subgroups. Higher baseline levels of serum biomarkers were observed in the BIO-IT group vs. the non-BIO-IT group, as well as in those with a BASDAI ≥ 4 vs. those with a BASDAI < 4. Increasing levels of several biomarkers were observed in SpA, especially in the BIO-IT and BASDAI ≥ 4 subgroups throughout the timeline kinetics, with impairment/disturbance in the IFN-γ/IL-10 axis around the peak of viremia (D5). Altogether, these findings suggested that the use of biological DMARDs impacts the response to the 17DD-YF vaccine, even after planned washout. Therefore, previous biological DMARD therapy, the inflammatory status prior vaccination, and impairment of the IFN-γ/IL-10 axis at the peak of viremia may determine the immunogenicity of 17DD-YF vaccination in patients with SpA. | en_US |
Affilliation | Universidade Federal do Espírito Santo. Hospital Universitário Cassiano Antônio Moraes. Vitória, ES, Brazil/Universidade Federal do Espírito Santo. Programa de Pós-graduação em Saúde Coletiva. Vitória, ES, Brazil. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil. | en_US |
Affilliation | Universidade Federal do Espírito Santo. Hospital Universitário Cassiano Antônio Moraes. Vitória, ES, Brazil | en_US |
Affilliation | Universidade Federal do Espírito Santo. Hospital Universitário Cassiano Antônio Moraes. Vitória, ES, Brazil | en_US |
Affilliation | Universidade Federal do Espírito Santo. Hospital Universitário Cassiano Antônio Moraes. Vitória, ES, Brazil | en_US |
Affilliation | Universidade Federal do Espírito Santo. Hospital Universitário Cassiano Antônio Moraes. Vitória, ES, Brazil | en_US |
Affilliation | Universidade Federal do Espírito Santo. Hospital Universitário Cassiano Antônio Moraes. Vitória, ES, Brazil/ Santa Casa de Misericórdia. Escola de Ciências da Saúde. Vitória, ES, Brazil. | en_US |
Affilliation | Universidade Federal do Espírito Santo. Hospital Universitário Cassiano Antônio Moraes. Vitória, ES, Brazil/Universidade Federal do Espírito Santo. Programa de Pós-graduação em Saúde Coletiva. Vitória, ES, Brazil. | en_US |
Affilliation | Universidade Federal do Espírito Santo. Programa de Pós-graduação em Biotecnologia. Vitória, ES, Brazil. | en_US |
Affilliation | Universidade Federal do Espírito Santo. Hospital Universitário Cassiano Antônio Moraes. Vitória, ES, Brazil | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil. | en_US |
Affilliation | Universidade Federal do Espírito Santo. Hospital Universitário Cassiano Antônio Moraes. Vitória, ES, Brazil | en_US |
Affilliation | Universidade Federal do Espírito Santo. Hospital Universitário Cassiano Antônio Moraes. Vitória, ES, Brazil/Universidade Federal do Espírito Santo. Programa de Pós-graduação em Saúde Coletiva. Vitória, ES, Brazil. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brazil. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brazil. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brazil. | en_US |
Affilliation | Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância das Doenças Transmissíveis. Brasília, DF, Brazil. | en_US |
Affilliation | Centro Regional de Imunobiológicos Especiais. Vitória, ES, Brazil. | en_US |
Affilliation | Santa Casa de Misericórdia. Escola de Ciências da Saúde. Vitória, ES, Brazil. | en_US |
Affilliation | Universidade de Brasília. Faculdade de Medicina. Hospital Universitário de Brasília. Serviço de Reumatologia. Programa de Pós-graduação em Ciências Médicas. Brasília, DF, Brazil. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil. | en_US |
Affilliation | Universidade Federal do Espírito Santo. Hospital Universitário Cassiano Antônio Moraes. Vitória, ES, Brazil/Universidade Federal do Espírito Santo. Programa de Pós-graduação em Saúde Coletiva. Vitória, ES, Brazil. | en_US |
Subject | 17DD-YF vaccine | en_US |
Subject | Biological DMARD | en_US |
Subject | Chemokines; Cytokines | en_US |
Subject | Serum soluble biomarkers | en_US |
Subject | Spondyloarthritis | en_US |
Subject | Yellow fever | en_US |
Subject | Yellow fever vaccine | en_US |
Embargo date | 2099-12-31 | |